VF
CLRB icon

Virtu Financial’s Cellectar Biosciences CLRB Stock Holding History

Virtu Financial’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-51
Closed -$6K – 1785
2022
Q2 		$6K Buy
+51
New +$7.28K ﹤0.01% 1450
2022
Q1 		– Sell
-125
Closed -$25K – 1560
2021
Q4 		$25K Buy
+125
New +$30.1K ﹤0.01% 1485
2021
Q3 		– Sell
-166
Closed -$59K – 1558
2021
Q2 		$59K Buy
+166
New +$72K 0.01% 1307
2021
Q1 		– Sell
-756
Closed -$472K – 1650
2020
Q4 		$472K Buy
+756
New +$347K 0.05% 457
2018
Q3 		– Sell
-32
Closed -$59K – 1604
2018
Q2 		$59K Buy
+32
New +$98.3K ﹤0.01% 1730
2018
Q1 		– Sell
-13
Closed -$55K – 2024
2017
Q4 		$55K Buy
+13
New +$58.1K ﹤0.01% 2065

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial's CLRB Position: Q3 2022 in Review

Virtu Financial sold out of Cellectar Biosciences (CLRB) in Q3 2022, closing a stake of 51 shares — an estimated $6K sold.

Virtu Financial first reported a position in CLRB in Q4 2017 and held it in 6 quarters. The position peaked at $472K in Q4 2020. 20 funds tracked by Wall St. Rank hold CLRB as of Q3 2022.

  • Virtu Financial reported no remaining Cellectar Biosciences position as of Q3 2022 after selling out during the quarter.
  • Virtu Financial sold 51 Cellectar Biosciences shares in Q3 2022, an estimated $6K.
  • Virtu Financial first reported a position in Cellectar Biosciences in Q4 2017 and held it in 6 quarters.
  • Virtu Financial's Cellectar Biosciences position peaked at $472K in Q4 2020.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2022.

Based on Virtu Financial's 13F filing for Q3 2022, filed 7 Nov 2022.